GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » Accounts Payable & Accrued Expense

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Accounts Payable & Accrued Expense : $12.07 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co Accounts Payable & Accrued Expense?

JW (Cayman) Therapeutics Co's quarterly accounts payable & accrued expense declined from Dec. 2022 ($17.85 Mil) to Jun. 2023 ($9.40 Mil) but then increased from Jun. 2023 ($9.40 Mil) to Dec. 2023 ($12.07 Mil).

JW (Cayman) Therapeutics Co's annual accounts payable & accrued expense declined from Dec. 2021 ($21.19 Mil) to Dec. 2022 ($17.85 Mil) and declined from Dec. 2022 ($17.85 Mil) to Dec. 2023 ($12.07 Mil).

JW (Cayman) Therapeutics Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Accounts Payable & Accrued Expense Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial 10.74 12.75 21.19 17.85 12.07

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 21.19 16.07 17.85 9.40 12.07

JW (Cayman) Therapeutics Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » Accounts Payable & Accrued Expense
Comparable Companies
HKSE:02197 HKSE:02185 HKSE:06996 HKSE:06998 HKSE:03681 HKSE:01228 HKSE:02142 HKSE:09939 HKSE:01875 HKSE:00690 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
02126:Hong Kong
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
Website
https://www.jwtherapeutics.com
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Headlines

No Headlines